Group by Gene: BCL Inhibitors Chemotherapy EGFR Tyrosine Kinase Inhibitors DNA Immunotherapy CD Protein Inhibitors Immune Checkpoint Inhibitors | Thymidylate synthase inhibitor capecitabine | 5-fluorouracil | DNA synthesis inhibitor cisplatin | Tubulin polymerization promoter, Bcl2 inhibitor carboplatin + paclitaxel | paclitaxel | DNA synthesis inhibitor, Topoisomerase I inhibitor cisplatin + irinotecan | EGFR inhibitor cetuximab | pembrolizumab | PD1 inhibitor sintilimab | toripalimab-tpzi | nivolumab | PD1 inhibitor, CTLA4 inhibitor nivolumab + ipilimumab | TLR7 agonist, TLR8 agonist imiquimod | DNA synthesis inhibitor, Thymidylate synthase inhibitor cisplatin + 5-fluorouracil | 5-fluorouracil + mitomycin | Chemotherapy TIP |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||||||||||
TMB-H + PD-L1 expression | ||||||||||||||||
PD-L1 expression | ||||||||||||||||
MSI-L/dMMR | ||||||||||||||||
MSI-H/dMMR | ||||||||||||||||
TMB-H + PD-L1 expression + MSI-L/dMMR | ||||||||||||||||
TMB-H | ||||||||||||||||
CDKN2A mutation |